Nonclinical safety assessment of SPX-101, a novel peptide promoter of epithelial sodium channel internalization for the treatment of cystic fibrosis.
about
Nonclinical safety assessment of SPX-101, a novel peptide promoter of epithelial sodium channel internalization for the treatment of cystic fibrosis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Nonclinical safety assessment ...... treatment of cystic fibrosis.
@en
Nonclinical safety assessment ...... treatment of cystic fibrosis.
@nl
type
label
Nonclinical safety assessment ...... treatment of cystic fibrosis.
@en
Nonclinical safety assessment ...... treatment of cystic fibrosis.
@nl
prefLabel
Nonclinical safety assessment ...... treatment of cystic fibrosis.
@en
Nonclinical safety assessment ...... treatment of cystic fibrosis.
@nl
P2093
P2860
P1476
Nonclinical safety assessment ...... treatment of cystic fibrosis.
@en
P2093
Dale Christensen
Matt Cowlen
Matthew P Walker
Mutsumi Miyamoto
Phillip Barley
Timothy Crowder
P2860
P304
P356
10.1080/08958378.2017.1366602
P577
2017-10-06T00:00:00Z